Optimize the combination regimen of Trastuzumab and Nab-paclitaxel in HER2-positive tumors via modulating Caveolin-1 expression by lovastatin

The combination regimen of trastuzumab (Tras) plus Nab-paclitaxel (Nab) is recommended to treat HER2-positive (HER2(+)) cancers. However, they exert effects in different mechanisms: Tras need to stay on cell membranes, while Nab need to be endocytosed, therefore the concurrent combination regimen ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Canyu, Fan, Shumin, Wang, Xing, Liu, Wei, Yang, Long, He, Bing, Dai, Wenbing, Zhang, Hua, Wang, Xueqing, Zhang, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Shenyang Pharmaceutical University 2022
Materias:
Original Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9640369/
https://www.ncbi.nlm.nih.gov/pubmed/36382307
http://dx.doi.org/10.1016/j.ajps.2022.06.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9640369/
https://www.ncbi.nlm.nih.gov/pubmed/36382307
http://dx.doi.org/10.1016/j.ajps.2022.06.002

Ejemplares similares